

BrainCool AB (publ): A new patent application for RhinoChill technology paves the way for new possibilities

The patent application for a newly developed technology resulting in updated cooling systems of RhinoChill, has reduced its weight significantly, from 13 kg to only 5 kg. Even the size has been reduced.

- * *The development of the product has been fully financed within the framework of two EU grants.*
- * *The clinical results of the Princess 2 also apply to the new lighter generation of the device*

The new generation of RhinoChill will be evaluated in collaboration with Karolinska Institutet (1) in a substudy to Princess 2, with the aim of:

- * *evaluating the effectiveness and feasibility of the compact RhinoChill version in a real clinical setting.*
- * *further validating its potential applications and overall performance.*

BrainCool and Karolinska will seek additional funding to support the substudy and the final stages of product development leading to market approval.

The new lightweight generation RhinoChill, creates new possibilities and will also target new areas such as:

- * *traumatic brain injuries (TBI) in the military market*
- * *the growing medical problem of heat stroke caused by climate change.*

BrainCool's goal is to introduce a new standard of care with cooling technology in public settings, schools and sports facilities, similar to the implementation of defibrillators/AEDs.

CEO Martin Waleij comments:

"In conclusion, access to fast and flexible cooling is critical to optimizing patient outcomes. The new generation of compact Rhinochill is three times lighter and can be easily adapted to different situations and they can be easily transported.

Please note that the commercial launch of the new cooling therapy for heart patients following the completion of the Princess 2 study, will only include the new generation RhinoChill (5 kg)."

For more information about the Princess 2 study and BrainCool's products, see the video below, where Dr. Per Nordberg briefly describes how to include and manage a study patient.

[Princess2 trial movie - YouTube](#)

Reference

(1) <https://www.mfn.se/cis/a/braincool/braincool-ab-publ-braincool-levererar-rhinochill-r-system-till-karolinska-institutet-for-banbrytande-studie-inom-tidig-kylning-som-kan-etablera-en-ny-medicinsk-indikation-vid-hjartstopp-3fecf286>

Contacts**For more information**

Martin Waleij - CEO

+46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

About Us

BrainCool AB (publ) is an innovative medical device company that develops, markets, and sells leading medical cooling systems for indications and areas with significant medical benefits within the healthcare sector. The company focuses on two business segments, Brain Cooling and Oncology.

BrainCool AB (publ) is based in Lund, Sweden, and its share is listed on Nasdaq First North Growth Market, named "BRAIN".

Eminova Fondkommission AB is the company's Certified Adviser.

Attachments

[BrainCool AB \(publ\): A new patent application for RhinoChill technology paves the way for new possibilities](#)